诱导化疗在局部晚期头颈部鳞癌治疗中的应用  

The application of induction chemotherapy in the treatment of locally advanced head and neck squamous cell carcinoma

作　　者：周梁 Liang Zhou(ENT Institute and Department of Otorhinolaryngology,Eye&ENT Hospital of Fudan University,Shanghai 200031,China)

机构地区：[1]复旦大学附属眼耳鼻喉科医院耳鼻咽喉头颈外科,上海200031

出　　处：《中华医学杂志》2024年第26期2373-2377,共5页National Medical Journal of China

摘　　要：对手术无法保留喉功能的局部晚期头颈部鳞癌,同步放化疗是目前标准的非手术治疗方法。诱导化疗+放/化疗也是常用策略之一。然而,诱导化疗除了在喉功能保留和对局部晚期头颈部鳞癌治疗方案的筛选中具有作用外,能否为患者带来生存获益仍存在争议。该文结合诱导化疗在局部晚期头颈部鳞癌治疗中的进展,就诱导化疗的标准方案、保喉作用、能否预测头颈部鳞癌对放化疗的疗效、能否带来远处转移率下降和生存获益、在人乳头瘤病毒(HPV)阳性头颈部鳞癌中诱导化疗后能否降低治疗强度及免疫治疗在局部晚期头颈部鳞癌诱导化疗中的应用等问题进行探讨。Standard treatment for patients with locally advanced head and neck squamous cell carcinoma(LAHNSCC)whose larynx could not be preserved surgically consists mainly of concurrent chemoradiotherapy(CCRT).Induction chemotherapy(ICT)followed by radiotherapy or chemoradiotherapy is also an alternative option.However,whether ICT could provide survival benefits for patients with LAHNSCC,besides its role in laryngeal preservation and selecting the treatment modality,is still controversial.The article summarizes the current position of ICT for LAHNSCC and discusses the standard regimen of ICT,its role in larynx preservation,its ability to predicting the result of chemoradiotherapy,clinical outcomes regarding the survival benefits after ICT,its role in the treatment deintensification for human papillomavirus-positive LAHNSCC and its application in the era of immunotherapy.

关 键 词：头颈部肿瘤 癌 鳞状细胞 诱导化疗 

分 类 号：R739.91[医药卫生—肿瘤]